Dynamic Covalent Chemistry
FULL PAPER
CDCl3): d=159.9, 138.2, 132.4, 130.8, 128.2, 128.1, 121.3, 121.2, 51.1, 21.3;
(3.18 mg, 0.021 mmol, 1 equiv). 1H NMR (400 MHz, 298 K, CDCl3): d=
8.53 (s, 1H, imine), 7.68 (d, J=7 Hz, 1H, 6-iminophenylboronic ester),
7.64 (d, J=7.5 Hz, 1H, 3-iminophenylboronic ester), 7.60 (dt, J=7.5 Hz,
J’=1 Hz, 1H, 5-iminophenylboronic ester), 7.42 (dt, J=7.5 Hz, J’=1 Hz,
1H, 4-iminophenylboronic ester), 7.25 (d, J=8 Hz, 2H, aniline next to
imine), 7.09 (d, J=8 Hz, 2H, aniline next to -Me), 6.85 (m, 2H, catecho-
late), 6.75 (m, 2H, catecholate), 2.30 ppm (s, 3H, -CH3); 11B NMR
(641.85 MHz, 298 K) CDCl3: d=15.1 ppm; MeOD: d=14.7 ppm;
13C NMR (100.62 MHz, 298 K, CDCl3): d=166.2, 152.2, 139.6, 138.6,
137.3, 134.9, 131.3, 130.3, 129.1, 127.5, 121.9, 119.5, 110.3, 21.2 ppm. EI-
MS: 313 [3A]+.
EI-MS: 267 [3
(OMe)2]+.
A
11A (Method A): Pyrocatechol A (3.16 mg, 0.029 mmol, 1 equiv), 2-me-
thoxyethylamine (11; 2.15 mg, 0.029 mmol, 1 equiv), 2-formylphenylbor-
onic acid (4.29 mg, 0.029 mmol, 1 equiv). 1H NMR (400 MHz, 298 K,
CDCl3): d=8.34 (s, 1H, imine), 7.65 (d, J=7 Hz, 1H, 6-iminophenylbor-
onic ester), 7.54 (m, 2H, 3-iminophenylboronic ester + 5-iminophenyl-
boronic ester), 7.38 (dt, J=7.5 Hz, J’=1 Hz, 1H, 4-iminophenylboronic
ester), 6.88 (m, 2H, catecholate), 6.77 (m, 2H, catecholate), 3.65 (m, 2H,
-CH=N-CH2CH2OCH3), 3.58 (m, 2H, -CH=N-CH2CH2OCH3), 3.35 ppm
(s, 3H, -CH=N-CH2CH2OCH3); 11B NMR (641.85 MHz, 298 K) CDCl3:
d=13.3 ppm; MeOD: d=10.9 ppm; 13C NMR (100.62 MHz, 298 K,
CDCl3): d=170.1, 152.4, 137.9, 134.2, 131.1, 128.8, 26.9, 119.4, 110.3, 69.3,
59.1, 49.7 ppm; EI-MS: 281 [11A]+, 250 [11AꢀCH3O]+, 236
3B (Method A): 1,2-Ethanediol (B; 21.70 mg, 0.345 mmol, 1 equiv), p-tol-
uidine (3; 37.46 mg, 0.345 mmol, 1 equiv), 2-formylphenylboronic acid
1
(52.42 mg, 0.345 mmol, 1 equiv), and MeOH (4 mL). H NMR (400 MHz,
[11AꢀCH3OCH2]+,
222
[11AꢀCH3OCH2CH2]+,
209
298 K, CDCl3): d=8.60 (s, 1H, imine), 7.71 (dd, J=8 Hz, 2H, 3-imino-
phenylboronic ester + 6-iminophenylboronic ester), 7.50 (t, J=7.5 Hz,
1H, 5-iminophenylboronic ester), 7.41 (t, J=7.5 Hz, 1H, 4-iminophenyl-
boronic ester), 7.31 (d, J=8 Hz, 2H, aniline nexte to imine), 7.23 (d, J=
8 Hz, 2H, aniline next to -Me), 4.15 (brs, 4H, -OCH2CH2O-), 2.40 ppm
(s, 3H, -CH3); 11B NMR (641.85 MHz, 298 K) CDCl3: d=22.9 ppm;
MeOD: d=14.7 ppm; 13C NMR (100.62 MHz, 298 K, CDCl3): d=163.1,
139.4, 137.7, 132.7, 132.4, 130.1, 129.4, 127.7, 121.8, 65.6, 21.4 ppm; EI-
MS: 265 [3B]+.
[11AꢀCH3OCH2CH2N]+.
11B (Method A): 1,2-Ethanediol B (1.8 mL, 0.032 mmol, 1 equiv), 2-me-
thoxyethylamine (11; 2.40 mg, 0.032 mmol, 1 equiv), 2-formylphenylbor-
onic acid (4.78 mg, 0.032 mmol, 1 equiv). 1H NMR (400 MHz, 298 K,
CDCl3): d=8.30 (s, 1H, imine), 7.57 (d, J=7 Hz, 1H, 6-iminophenylbor-
onic ester), 7.45 (m, 2H, 3-iminophenylboronic ester + 5-iminophenyl-
boronic ester), 7.28 (t, J=8 Hz, 1H, 4-iminophenylboronic ester), 4.13 (s,
4H, -OCH2CH2O-), 3.80 (t, J=5 Hz, 2H, -CH=N-CH2CH2OCH3), 3.74
(t, J=5 Hz, 2H, -CH=N-CH2CH2OCH3), 3.37 ppm (s, 3H, -CH=N-
CH2CH2OCH3); 13C NMR (100.62 MHz, 298 K, CDCl3): d=168.8, 137.9,
133.4, 130.5, 127.9, 126.2, 69.9, 65.5, 59.1, 50.4 ppm; EI-MS: 233 [11B]+,
4A (Method A): Pyrocatechol (A; 2.80 mg, 0.025 mmol, 1 equiv), 4-
(methylmercapto)aniline (4; 3.54 mg, 0.025 mmol, 1 equiv), 2-formylphe-
nylboronic acid (3.81 mg, 0.025 mmol, 1 equiv). 1H NMR (400 MHz,
298 K, CDCl3): d=8.55 (s, 1H, imine), 7.63 (m, 3H, 3-iminophenylboron-
ic ester + 5-iminophenylboronic ester + 6-iminophenylboronic ester),
7.42 (t, J=7.5 Hz, 1H, 4-iminophenylboronic ester), 7.27 (d, overlapped
signal with CHCl3, 2H, aniline next to imine), 7.11 (d, J=8.5 Hz, 2H,
aniline next to -SMe), 6.86 (m, 2H, catecholate), 6.77 (m, 2H, catecho-
late), 2.43 ppm (s, 3H, -SCH3); 13C NMR (100.62 MHz, 298 K, CDCl3):
d=165.8, 152.0, 140.9, 137.8, 137.2, 134.9, 131.3, 129.2, 127.6, 126.7, 122.4,
119.6, 110.4, 15.4; EI-MS: 345 [4A]+, 330 [4AꢀCH3]+.
5A (Method A): Pyrocatechol (A; 2.65 mg, 0.024 mmol, 1 equiv), 4-io-
doaniline (5; 5.28 mg, 0.024 mmol, 1 equiv), 2-formylphenylboronic acid
(3.61 mg, 0.024 mmol, 1 equiv). 1H NMR (400 MHz, 298 K, CDCl3): d=
8.55 (s, 1H, imine), 7.65 (m, 5H, 3-iminophenylboronic ester + 5-imino-
phenylboronic ester + 6-iminophenylboronic ester + aniline nexte to
imine), 7.43 (t, J=7 Hz, 1H, 4-iminophenylboronic ester), 7.08 (d, J=
8.5 Hz, 2H, aniline next to -I), 6.86 (m, 2H, catecholate), 6.78 ppm (m,
2H, catecholate); 13C NMR (100.62 MHz, 298 K, CDCl3): d=167.2,
151.8, 140.7, 138.8, 137.0, 135.3, 131.4, 129.3, 128.0, 123.8, 120.8, 119.8,
110.5, 94.9 ppm; EI-MS: 425 [5A]+.
203
[11BꢀCH3O]+,
188
[11BꢀCH3OCH2]+,
161
[11BꢀCH3OCH2CH2N]+.
11C (Method A): 1,3-Propanediol C (2.8 mL, 0.039 mmol, 1 equiv), 2-me-
thoxyethylamine 11 (2.93 mg, 0.039 mmol, 1 equiv), 2-formylphenylbor-
onic acid (5.85 mg, 0.039 mmol, 1 equiv). 1H NMR (400 MHz, 298 K,
CDCl3): d=8.50 (s, 1H, imine), 7.60 (m, 2H, 6-iminophenylboronic ester
+ 3-iminophenylboronic ester), 7.41 (dt, J=7 Hz, J’=1 Hz, 1H, 5-imino-
phenylboronic ester), 7.32 (dt, J=7.5 Hz, J’=1.5 Hz, 1H, 4-iminophenyl-
boronic ester), 4.14 (t, J=5.5 Hz, 4H, -OCH2CH2CH2O-), 3.87 (t, J=
6 Hz, 2H, -CH=N-CH2CH2OCH3), 3.74 (t, J=5.5 Hz, 2H, -CH=N-
CH2CH2OCH3), 3.39 (s, 3H, -CH=N-CH2CH2OCH3), 2.04 ppm (quint.,
J=5.5 Hz, 2H, -OCH2CH2CH2O-); 13C NMR (100.62 MHz, 298 K,
CDCl3): d=165.9, 139.0, 131.9, 131.2, 128.6, 127.4, 71.6, 62.0, 59.1, 57.1,
28.3 ppm ;
EI-MS:
247
188
[11C]+,
217
[11CꢀCH3O]+,
202
175
[11CꢀCH3OCH2]+,
[11CꢀCH3OCH2CH2]+,
[11CꢀCH3OCH2CH2N]+.
1A (Method A): Pyrocatechol (A; 2.84 mg, 0.026 mmol, 1 equiv), 4-
amino-N,N-dimethylaniline (1; 3.50 mg, 0.025 mmol, 1 equiv), 2-formyl-
phenylboronic acid (3.86 mg, 0.026 mmol, 1 equiv). 1H NMR (400 MHz,
298 K, CDCl3): d=8.46 (s, 1H, imine), 7.64 (d, J=7 Hz, 1H, 6-iminophe-
nylboronic ester), 7.55 (m, 2H, 3-iminophenylboronic ester + 5-imino-
phenylboronic ester), 7.38 (dt, J=7.5 Hz, J’=1 Hz, 1H, 4-iminophenyl-
boronic ester), 7.23 (d, J=9 Hz, 2H, aniline next to imine), 6.88 (m, 2H,
catecholate), 6.78 (m, 4H, catecholate), 6.52 (d, J=9 Hz, 2H, aniline
6A (Method A): Pyrocatechol (A; 2.65 mg, 0.024 mmol, 1 equiv), 4-
chloroaniline (6; 3.06 mg, 0.024 mmol, 1 equiv), 2-formylphenylboronic
R
acid (3.61 mg, 0.024 mmol, 1 equiv). 1H NMR (400 MHz, 298 K, CDCl3):
d=8.58 (s, 1H, imine), 7.70 (m, 3H, 3-iminophenylboronic ester + 5-imi-
nophenylboronic ester + 6-iminophenylboronic ester), 7.48 (t, J=7.5 Hz,
1H, 4-iminophenylboronic ester), 7.32, (m, 4H, aniline), 6.90 (m, 2H,
catecholate), 6.81 ppm (m, 2H, catecholate);. 13C NMR (100.62 MHz,
298 K, CDCl3): d=167.1, 151.9, 139.6, 137.1, 135.3, 131.5, 129.9, 129.3,
127.9, 123.5, 119.8, 110.5 ppm. EI-MS: 333 [6A]+.
next to NMe2), 2.93 ppm (s, 6H, -N
(CH3)2); 11B NMR (641.85 MHz,
H
298 K) CDCl3: d=15.0 ppm; MeOD: d=13.6 ppm.; 13C NMR
(100.62 MHz, 298 K, CDCl3): d =161.6, 152.3, 150.8, 137.6, 133.9, 131.0,
129.7, 128.9, 126.6, 122.9, 119.4, 112.3, 110.3, 40.3 ppm; ES-MS: 372
[1A+MeO]ꢀ.
112D (Method B): Pentaerythritol (D; 3.20 mg, 0.023 mmol, 1 equiv), 2-
methoxyethylamine (11; 3.54 mg, 0.047 mmol, 2 equiv), 2-formylphenyl-
boronic acid (7.06 mg, 0.047 mmol, 2 equiv). 1H NMR (400 MHz, 298 K,
CDCl3): d=8.37 (s, 1H, imine), 7.69 (d, J=7 Hz, 1H, 6-iminophenylbor-
onic ester), 7.50 (d, J=7.5 Hz, 1H, 3-iminophenylboronic ester), 7.45 (t,
J=7.5 Hz, 1H, 5-iminophenylboronic ester), 7.29 (t, J=7.5 Hz, 1H, 4-
iminophenylboronic ester), 4.09 (s, 4H, -OCH2CCH2O-), 3.93 (t, J=5 Hz,
2H, -CH=N-CH2CH2OCH3), 3.77 (t, J=5 Hz, 2H, -CH=N-
CH2CH2OCH3), 3.39 ppm (s, 3H, -CH=N-CH2CH2OCH3); 13C NMR
(100.62 MHz, 298 K, CDCl3): d =168.3, 137.8, 132.8, 130.6, 127.9, 127.0,
70.5, 66.1 (two overlapping peaks), 59.1, 53.1 ppm; EI-MS: 478 [112D]+,
2A (Method A): Pyrocatechol (A; 2.65 mg, 0.024 mmol, 1 equiv), 4-me-
thoxyaniline (2; 3.01 mg, 0.025 mmol, 1 equiv), 2-formylphenylboronic
acid (3.61 mg, 0.024 mmol, 1 equiv). 1H NMR (400 MHz, 298 K, CDCl3):
d=8.50 (s, 1H, imine), 7.67 (d, J=7 Hz, 1H, 6-iminophenylboronic
ester), 7.60 (m, 2H, 3-iminophenylboronic ester + 5-iminophenylboronic
ester), 7.42 (dt, J=7.5 Hz, J’=1 Hz, 1H, 4-iminophenylboronic ester),
7.30 (d, J=9 Hz, 2H, aniline next to imine), 6.84 (m, 2H, catecholate),
6.77 (m, 4H, aniline next to -OMe + catecholate), 3.76 ppm (s, 3H,
-OCH3); 13C NMR (100.62 MHz, 298 K, CDCl3): d =165.1, 160.3, 152.1,
137.3, 134.7, 134.0, 131.2, 129.1, 127.3, 123.4, 119.5, 114.9, 110.4,
55.6 ppm; EI-MS: 329 [2A]+, 314 [2AꢀCH3]+.
447
[112DꢀOCH3]+,
443
[112DꢀCH3OCH2]+,
419
[112DꢀCH3OCH2CH2]+.
3A (Method A): Pyrocatechol (A; 2.33 mg, 0.021 mmol, 1 equiv), p-tolui-
dine (3; 2.28 mg, 0.021 mmol, 1 equiv), 2-formylphenylboronic acid
15A2
(Method B): Pyrocatechol (A; 2.30 mg, 0.021 mmol, 2 equiv), bis
ACHTREUNG
amino)diphenyl ether (15; 4.18 mg, 0.010 mmol, 1 equiv), 2-formylphenyl-
Chem. Eur. J. 2008, 14, 4585 – 4593
ꢀ 2008 Wiley-VCH Verlag GmbH & Co.KGaA, Weinheim
4591